Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma

8 Jan 2016

Abstract excerpt

Recent clinical trials have demonstrated that targeting chromatin remodeling factors is as a promising strategy for the treatment of glioblastoma (GBM). We and others have shown constitutive activation of DNA damage response (DDR) pathways in gliomas and suggested that targeting the DDR may improve the currently grim prognosis for patients. Based on our previous findings that inhibition of poly(ADP-ribose)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to Glioma Diagnosis and Treatment
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26794465
DOI: 10.1016/j.molonc.2015.12.014

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Enhanced efficacy of combined HDAC and PARP targeting in glioblastomaPMID 26794465Read ↗

Overcoming Resistance of Glioblastoma to Conventional Cytotoxic Therapies by the Addition of PARP InhibitorsSemantic proximity Read ↗

PARP Inhibitors in Glioma: A Review of Therapeutic OpportunitiesSemantic proximity Read ↗

DNA damage response and anti-apoptotic proteins predict radiosensitization efficacy of HDAC inhibitors SAHA and LBH589 in patient-derived glioblastoma cellsSemantic proximity Read ↗

PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular HeterogeneitySemantic proximity Read ↗

Rad51 and BRCA2 - New Molecular Targets for Sensitizing Glioma Cells to Alkylating Anticancer DrugsSemantic proximity Read ↗

HDAC4 and HDAC6 sustain DNA double strand break repair and stem-like phenotype by promoting radioresistance in glioblastoma cells.Semantic proximity Read ↗

Role of PARP Inhibitors in Glioblastoma and Perceiving Challenges as Well as Strategies for Successful Clinical DevelopmentSemantic proximity Read ↗

Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation TherapySemantic proximity Read ↗

Olaparib: A Chemosensitizer for the Treatment of GlioblastomaSemantic proximity Read ↗

Therapeutic Application of PARP Inhibitors in Neuro-Oncology.Semantic proximity Read ↗

Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?Semantic proximity Read ↗

Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in GlioblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.